Ondine Biomedical Inc.

LSE OBI.L

Ondine Biomedical Inc. Shares (Diluted, Weighted) for the year ending December 31, 2023: 197,111,567

Ondine Biomedical Inc. Shares (Diluted, Weighted) is 197,111,567 for the year ending December 31, 2023, a 1.30% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Ondine Biomedical Inc. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 194,588,245, a 144.34% change year over year.
Ondine Biomedical Inc. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 79,637,956, a -59.07% change year over year.
Ondine Biomedical Inc. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 194,584,524, a 0.00% change year over year.
Ondine Biomedical Inc. Shares (Diluted, Weighted) for the year ending December 31, 2019 was 194,584,524, a 0.00% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

LSE: OBI.L

Ondine Biomedical Inc.

CEO	Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA
IPO Date	Dec. 6, 2021
Location	Canada
Headquarters	1100 Melville Street
Employees	18
Sector	Healthcare
Industries Biotechnology 3D Printing Cleaning Supplies Eyewear Personal Care Pharmaceuticals Pollution Treatment Vaccines

Description

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

Key trends

Past 5 years